Costs of drug treatment in Parkinson's disease.
Identifieur interne : 004475 ( PubMed/Corpus ); précédent : 004474; suivant : 004476Costs of drug treatment in Parkinson's disease.
Auteurs : R C Dodel ; K M Eggert ; M S Singer ; T E Eichhorn ; O. Pogarell ; W H OertelSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 1998.
English descriptors
- KwdEn :
- Antiparkinson Agents (adverse effects), Antiparkinson Agents (economics), Antiparkinson Agents (therapeutic use), Costs and Cost Analysis, Dopamine Agonists (adverse effects), Dopamine Agonists (economics), Dopamine Agonists (therapeutic use), Drug Costs (statistics & numerical data), Drug Therapy, Combination, Germany, Humans, Levodopa (adverse effects), Levodopa (economics), Levodopa (therapeutic use), National Health Programs (economics), Neurologic Examination (drug effects), Parkinson Disease (classification), Parkinson Disease (drug therapy), Parkinson Disease (economics).
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Dopamine Agonists, Levodopa.
- chemical , economics : Antiparkinson Agents, Dopamine Agonists, Levodopa.
- chemical , therapeutic use : Antiparkinson Agents, Dopamine Agonists, Levodopa.
- geographic : Germany.
- classification : Parkinson Disease.
- drug effects : Neurologic Examination.
- drug therapy : Parkinson Disease.
- economics : National Health Programs, Parkinson Disease.
- statistics & numerical data : Drug Costs.
- Costs and Cost Analysis, Drug Therapy, Combination, Humans.
Abstract
Parkinson's disease (PD) has a major socioeconomic impact on society. The chronic, progressive course of the disease, which often leads to severe disability, results in high expenses for the medical resources used for treatment, care, and rehabilitation of patients as well as reduced or lost productivity as a result of illness or premature death. In Great Britain, it has been estimated that the National Health Service spends up to 383 million pound sterling (1992) annually for the care of PD. This emphasizes the importance of assessing the costs related to this disease. A detailed knowledge of the cost allocation would provide a solid basis on which health care priorities can be rationally set. Next to hospitalization, drug treatment accounts for the highest expense for direct medical costs of PD. Therefore, this analysis focuses on the costs of drug treatment for PD. The cost analysis was based on a retrospective study of 409 patients with PD who were seen over a 1-year period in our movement disorders clinic. The cost of therapy varied considerably depending on the severity of the condition (assessed in the "off" phase), the incidence of motor fluctuations, and the type of PD. In the early stage of the disease (Hoehn and Yahr stage I [HY I]), mean daily costs for therapy were DM (German marks) 6.60, which increased in later stages of the disease (HY V) to DM 22.00. If rare cases requiring continuous subcutaneous apomorphine infusion were included, mean daily costs of patients in HY V rose to DM 32.50 (the mean daily costs of subcutaneous apomorphine-treated patients in HY V: DM 74.30). Patients with motor fluctuations accounted for higher costs (DM 16.50) compared with those without motor fluctuations (DM 7.80). With respect to the three subtypes of PD, the mean daily expenditure was DM 7.00 for the tremor-dominant type, DM 12.40 for the akinetic-rigid type, and DM 10.80 for the mixed type. In the group of 409 PD patients included in this analysis, the average daily expenditure for drug treatment totaled DM 10.70 per patient (including patients on subcutaneous apomorphine).
DOI: 10.1002/mds.870130209
PubMed: 9539337
Links to Exploration step
pubmed:9539337Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Costs of drug treatment in Parkinson's disease.</title>
<author><name sortKey="Dodel, R C" sort="Dodel, R C" uniqKey="Dodel R" first="R C" last="Dodel">R C Dodel</name>
<affiliation><nlm:affiliation>Department of Neurology, Ludwig-Maximilians-Universität, München, Germany.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Eggert, K M" sort="Eggert, K M" uniqKey="Eggert K" first="K M" last="Eggert">K M Eggert</name>
</author>
<author><name sortKey="Singer, M S" sort="Singer, M S" uniqKey="Singer M" first="M S" last="Singer">M S Singer</name>
</author>
<author><name sortKey="Eichhorn, T E" sort="Eichhorn, T E" uniqKey="Eichhorn T" first="T E" last="Eichhorn">T E Eichhorn</name>
</author>
<author><name sortKey="Pogarell, O" sort="Pogarell, O" uniqKey="Pogarell O" first="O" last="Pogarell">O. Pogarell</name>
</author>
<author><name sortKey="Oertel, W H" sort="Oertel, W H" uniqKey="Oertel W" first="W H" last="Oertel">W H Oertel</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="1998">1998</date>
<idno type="RBID">pubmed:9539337</idno>
<idno type="pmid">9539337</idno>
<idno type="doi">10.1002/mds.870130209</idno>
<idno type="wicri:Area/PubMed/Corpus">004475</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Costs of drug treatment in Parkinson's disease.</title>
<author><name sortKey="Dodel, R C" sort="Dodel, R C" uniqKey="Dodel R" first="R C" last="Dodel">R C Dodel</name>
<affiliation><nlm:affiliation>Department of Neurology, Ludwig-Maximilians-Universität, München, Germany.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Eggert, K M" sort="Eggert, K M" uniqKey="Eggert K" first="K M" last="Eggert">K M Eggert</name>
</author>
<author><name sortKey="Singer, M S" sort="Singer, M S" uniqKey="Singer M" first="M S" last="Singer">M S Singer</name>
</author>
<author><name sortKey="Eichhorn, T E" sort="Eichhorn, T E" uniqKey="Eichhorn T" first="T E" last="Eichhorn">T E Eichhorn</name>
</author>
<author><name sortKey="Pogarell, O" sort="Pogarell, O" uniqKey="Pogarell O" first="O" last="Pogarell">O. Pogarell</name>
</author>
<author><name sortKey="Oertel, W H" sort="Oertel, W H" uniqKey="Oertel W" first="W H" last="Oertel">W H Oertel</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="1998" type="published">1998</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (adverse effects)</term>
<term>Antiparkinson Agents (economics)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Costs and Cost Analysis</term>
<term>Dopamine Agonists (adverse effects)</term>
<term>Dopamine Agonists (economics)</term>
<term>Dopamine Agonists (therapeutic use)</term>
<term>Drug Costs (statistics & numerical data)</term>
<term>Drug Therapy, Combination</term>
<term>Germany</term>
<term>Humans</term>
<term>Levodopa (adverse effects)</term>
<term>Levodopa (economics)</term>
<term>Levodopa (therapeutic use)</term>
<term>National Health Programs (economics)</term>
<term>Neurologic Examination (drug effects)</term>
<term>Parkinson Disease (classification)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (economics)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Dopamine Agonists</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Dopamine Agonists</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Dopamine Agonists</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>Germany</term>
</keywords>
<keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Neurologic Examination</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>National Health Programs</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Drug Costs</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Costs and Cost Analysis</term>
<term>Drug Therapy, Combination</term>
<term>Humans</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Parkinson's disease (PD) has a major socioeconomic impact on society. The chronic, progressive course of the disease, which often leads to severe disability, results in high expenses for the medical resources used for treatment, care, and rehabilitation of patients as well as reduced or lost productivity as a result of illness or premature death. In Great Britain, it has been estimated that the National Health Service spends up to 383 million pound sterling (1992) annually for the care of PD. This emphasizes the importance of assessing the costs related to this disease. A detailed knowledge of the cost allocation would provide a solid basis on which health care priorities can be rationally set. Next to hospitalization, drug treatment accounts for the highest expense for direct medical costs of PD. Therefore, this analysis focuses on the costs of drug treatment for PD. The cost analysis was based on a retrospective study of 409 patients with PD who were seen over a 1-year period in our movement disorders clinic. The cost of therapy varied considerably depending on the severity of the condition (assessed in the "off" phase), the incidence of motor fluctuations, and the type of PD. In the early stage of the disease (Hoehn and Yahr stage I [HY I]), mean daily costs for therapy were DM (German marks) 6.60, which increased in later stages of the disease (HY V) to DM 22.00. If rare cases requiring continuous subcutaneous apomorphine infusion were included, mean daily costs of patients in HY V rose to DM 32.50 (the mean daily costs of subcutaneous apomorphine-treated patients in HY V: DM 74.30). Patients with motor fluctuations accounted for higher costs (DM 16.50) compared with those without motor fluctuations (DM 7.80). With respect to the three subtypes of PD, the mean daily expenditure was DM 7.00 for the tremor-dominant type, DM 12.40 for the akinetic-rigid type, and DM 10.80 for the mixed type. In the group of 409 PD patients included in this analysis, the average daily expenditure for drug treatment totaled DM 10.70 per patient (including patients on subcutaneous apomorphine).</div>
</front>
</TEI>
<pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">9539337</PMID>
<DateCreated><Year>1998</Year>
<Month>06</Month>
<Day>15</Day>
</DateCreated>
<DateCompleted><Year>1998</Year>
<Month>06</Month>
<Day>15</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN>
<JournalIssue CitedMedium="Print"><Volume>13</Volume>
<Issue>2</Issue>
<PubDate><Year>1998</Year>
<Month>Mar</Month>
</PubDate>
</JournalIssue>
<Title>Movement disorders : official journal of the Movement Disorder Society</Title>
<ISOAbbreviation>Mov. Disord.</ISOAbbreviation>
</Journal>
<ArticleTitle>Costs of drug treatment in Parkinson's disease.</ArticleTitle>
<Pagination><MedlinePgn>249-54</MedlinePgn>
</Pagination>
<Abstract><AbstractText>Parkinson's disease (PD) has a major socioeconomic impact on society. The chronic, progressive course of the disease, which often leads to severe disability, results in high expenses for the medical resources used for treatment, care, and rehabilitation of patients as well as reduced or lost productivity as a result of illness or premature death. In Great Britain, it has been estimated that the National Health Service spends up to 383 million pound sterling (1992) annually for the care of PD. This emphasizes the importance of assessing the costs related to this disease. A detailed knowledge of the cost allocation would provide a solid basis on which health care priorities can be rationally set. Next to hospitalization, drug treatment accounts for the highest expense for direct medical costs of PD. Therefore, this analysis focuses on the costs of drug treatment for PD. The cost analysis was based on a retrospective study of 409 patients with PD who were seen over a 1-year period in our movement disorders clinic. The cost of therapy varied considerably depending on the severity of the condition (assessed in the "off" phase), the incidence of motor fluctuations, and the type of PD. In the early stage of the disease (Hoehn and Yahr stage I [HY I]), mean daily costs for therapy were DM (German marks) 6.60, which increased in later stages of the disease (HY V) to DM 22.00. If rare cases requiring continuous subcutaneous apomorphine infusion were included, mean daily costs of patients in HY V rose to DM 32.50 (the mean daily costs of subcutaneous apomorphine-treated patients in HY V: DM 74.30). Patients with motor fluctuations accounted for higher costs (DM 16.50) compared with those without motor fluctuations (DM 7.80). With respect to the three subtypes of PD, the mean daily expenditure was DM 7.00 for the tremor-dominant type, DM 12.40 for the akinetic-rigid type, and DM 10.80 for the mixed type. In the group of 409 PD patients included in this analysis, the average daily expenditure for drug treatment totaled DM 10.70 per patient (including patients on subcutaneous apomorphine).</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dodel</LastName>
<ForeName>R C</ForeName>
<Initials>RC</Initials>
<AffiliationInfo><Affiliation>Department of Neurology, Ludwig-Maximilians-Universität, München, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Eggert</LastName>
<ForeName>K M</ForeName>
<Initials>KM</Initials>
</Author>
<Author ValidYN="Y"><LastName>Singer</LastName>
<ForeName>M S</ForeName>
<Initials>MS</Initials>
</Author>
<Author ValidYN="Y"><LastName>Eichhorn</LastName>
<ForeName>T E</ForeName>
<Initials>TE</Initials>
</Author>
<Author ValidYN="Y"><LastName>Pogarell</LastName>
<ForeName>O</ForeName>
<Initials>O</Initials>
</Author>
<Author ValidYN="Y"><LastName>Oertel</LastName>
<ForeName>W H</ForeName>
<Initials>WH</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>UNITED STATES</Country>
<MedlineTA>Mov Disord</MedlineTA>
<NlmUniqueID>8610688</NlmUniqueID>
<ISSNLinking>0885-3185</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>46627O600J</RegistryNumber>
<NameOfSubstance UI="D007980">Levodopa</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000191">economics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D003365">Costs and Cost Analysis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D018491">Dopamine Agonists</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000191">economics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D016527">Drug Costs</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000706">statistics & numerical data</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D004359">Drug Therapy, Combination</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" Type="Geographic" UI="D005858">Germany</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000191">economics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D009313">National Health Programs</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000191">economics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D009460">Neurologic Examination</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000145">classification</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000191">economics</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1998</Year>
<Month>4</Month>
<Day>16</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>1998</Year>
<Month>4</Month>
<Day>16</Day>
<Hour>0</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>1998</Year>
<Month>4</Month>
<Day>16</Day>
<Hour>0</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">9539337</ArticleId>
<ArticleId IdType="doi">10.1002/mds.870130209</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004475 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 004475 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:9539337 |texte= Costs of drug treatment in Parkinson's disease. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:9539337" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a MovDisordV3
![]() | This area was generated with Dilib version V0.6.23. | ![]() |